INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

Background Pediatric patients with relapsed or refractory disease represent a population with a desperate medical need. The aim of the INFORM (INdividualized Therapy FOr Relapsed Malignancies in Childhood) program is to translate next generation molecular diagnostics into a biomarker driven treatment strategy. The program consists of two major foundations: the INFORM registry providing a molecular screening platform and the INFORM2 series of biomarker driven phase I/II trials. The INFORM2 NivEnt trial aims to determine the recommended phase 2 dose (RP2D) of the combination treatment of nivolumab and entinostat (phase I) and to evaluate activity and safety (phase II). Methods This is an exploratory non-randomized, open-label, multinational and multicenter seamless phase I/II trial in children and adolescents with relapsed / refractory or progressive high-risk solid tumors and CNS tumors. The phase I is divided in 2 age cohorts: 12–21 years and 6–11 years and follows a 3 + 3 design with two dose levels for entinostat (2 mg/m 2 and 4 mg/m 2 once per week) and fixed dose nivolumab (3 mg/kg every 2 weeks). Patients entering the trial on RP2D can seamlessly enter phase II which consists of a biomarker defined four group basket trial: high mutational load (group A), high PD-L1 mRNA expression (group B), focal MYC(N) amplification (group C), low mutational load and low PD-L1 mRNA expression and no MYC(N) amplification (group D). A Bayesian adaptive design will be used to early stop cohorts that fail to show evidence of activity. The maximum number of patients is 128. Discussion This trial intends to exploit the immune enhancing effects of entinostat on nivolumab using an innovative biomarker driven approach in order to maximize the chance of detecting signs of activity. It prevents exposure to unnecessary risks by applying the Bayesian adaptive design for early stopping for futility. The adaptive biomarker driven design provides an innovative approach accelerating drug development and reducing exposure to investigational treatments in these vulnerable children at the same time. Trial registration ClinicalTrials.gov, NCT03838042 . Registered on 12 February 2019.

[1]  Bradley P. Carlin,et al.  Bayesian Adaptive Methods for Clinical Trials , 2010 .

[2]  Satoshi Teramukai,et al.  A Bayesian basket trial design that borrows information across strata based on the similarity between the posterior distributions of the response probability , 2019, Biometrical journal. Biometrische Zeitschrift.

[3]  David T. W. Jones,et al.  Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. , 2016, European journal of cancer.

[4]  Donald Kennedy,et al.  Breakthrough of the Year , 2007, Science.

[5]  J. Olson,et al.  HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. , 2016, Cancer cell.

[6]  G. Leverger,et al.  The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01 , 2014, Haematologica.

[7]  Yoon-Jae Cho,et al.  HIGH-THROUGHPUT DRUG SCREENING IDENTIFIES HDAC INHIBITORS AS CANDIDATE THERAPEUTICS FOR MYC-DRIVEN MEDULLOBLASTOMA , 2014 .

[8]  James R. Anderson,et al.  Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Geoerger,et al.  Patients in Pediatric Phase I and Early Phase II Clinical Oncology Trials at Gustave Roussy: A 13-Year Center Experience , 2015, Journal of pediatric hematology/oncology.

[10]  T. MacDonald,et al.  Treatment of high-grade glioma in children and adolescents. , 2011, Neuro-oncology.

[11]  D. Berry,et al.  Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials , 2013, Clinical trials.

[12]  G. Henze,et al.  Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. , 2011, European journal of cancer.

[13]  David T. W. Jones,et al.  Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. , 2013, The Lancet. Oncology.

[14]  Karl Broich,et al.  Master protocols in clinical trials: a universal Swiss Army knife? , 2019, The Lancet. Oncology.

[15]  M. Semik,et al.  Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  U. Dirksen,et al.  Risk of recurrence and survival after relapse in patients with Ewing sarcoma , 2011, Pediatric blood & cancer.

[17]  P. Jänne,et al.  Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy. , 2018 .

[18]  G. Adema,et al.  HDAC inhibitors and immunotherapy; a double edged sword? , 2014, Oncotarget.

[19]  D. Merico,et al.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L V Rubinstein,et al.  A comparison of two phase I trial designs. , 1994, Statistics in medicine.

[21]  Naoya Hashimoto,et al.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.

[22]  Publisher's Note , 2018, Anaesthesia.

[23]  K. Kinzler,et al.  Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells , 2014, Journal of Immunotherapy for Cancer.

[24]  P. Danaher,et al.  Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody. , 2018 .

[25]  F. Gilles,et al.  A retrospective analysis of recurrent intracranial ependymoma , 2014, Pediatric blood & cancer.

[26]  E. Haura,et al.  HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma , 2016, Clinical Cancer Research.

[27]  F. Berthold,et al.  Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Nakul M. Shah,et al.  DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats , 2017, Nature Genetics.

[29]  Annette Kopp-Schneider,et al.  Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions—A calibration approach , 2018, Biometrical journal. Biometrische Zeitschrift.

[30]  B. Chang,et al.  ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors. , 2018 .

[31]  S. Gettinger,et al.  Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[33]  J. Gil,et al.  Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. , 2012, Cancer letters.

[34]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[35]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[36]  C. Swanton,et al.  The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  R. Barr,et al.  Childhood Atypical Teratoid Rhabdoid Tumor of the Central Nervous System: A Meta-Analysis of Observational Studies , 2009, Journal of pediatric hematology/oncology.

[38]  Susan M. Chang,et al.  Response Assessment in Neuro-Oncology Clinical Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  David T. W. Jones,et al.  Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. , 2019, European journal of cancer.

[40]  M. Kool,et al.  Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma , 2015, Acta neuropathologica communications.

[41]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[42]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[43]  K. Davis,et al.  ADVL1412: Initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors—A COG study. , 2017 .

[44]  L. Ellis,et al.  Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models , 2012, PloS one.

[45]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[46]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[47]  K. Norga,et al.  Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  G. Long,et al.  Patterns of Response and Progression to Immunotherapy. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[49]  C. Anasetti,et al.  LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[50]  M. Cohen,et al.  Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.